Table 1.

Patient characteristics

Age at diagnosis (mean)61.7 (range, 23–89)
Sex (n, patients)
 Males69 (54.3%)
 Females58 (45.7%)
Stages (n, patients)
 IIIc14 (11.0%)
 IV113 (89.0%)
 M1a9 (7.1%)
 M1b23 (18.1%)
 M1c81 (63.8%)
Sites of metastasesa (n, patients)
 CNS49 (38.6%)
 Bone or soft tissue36 (23.8%)
 Visceral95 (74.8%)
 Lymph nodes96 (75.6%)
 Skin59 (46.5%)
BRAF mutation status (n, patients)
 Mutated42 (33.1%)
 Wild-type85 (66.9%)
Ipilimumab cycles (mean)3.34 (range, 1–8)
 ≤2 cycles (n, patients)31 (24.4%)
 ≥3 cycles (n, patients)95 (74.8%)
 n.a.b1 (0.8%)
Treatments during time of study (n, patients)
 Ipilimumab + LPT39 (30.7%)
 Ipilimumab + LPT + brain irradiation6 (4.7%)
 Ipilimumab only42 (33.1%)
 Ipilimumab + LBI17 (13.4%)
 Ipilimumab + WBI15 (11.8%)
 Ipilimumab + combination of LBI and WBI8 (7.1%)
Timing of LPT to ipilimumab (n, patients)
 Pre9 (20.0%)
 During19 (42.2%)
 Post17 (37.8%)
  • NOTE: Local brain irradiation (LBI) included stereotactic radiosurgery and cyberknife irradiation. WBI was conventionally performed. LPTs were defined as non-CNS-directed therapies and included the following: local irradiation (of lymph node, bone, visceral, or skin metastases) or skin-directed ECT or SIRT of liver metastases.

  • aPatients with more than one metastatic site were counted in every respective group. Timing of LPT referred to the entire ipilimumab treatment.

  • bn.a. refers to one patient who was retreated with 4 additional ipilimumab cycles following the initial 4-cycle treatment.